China’s First Automotive-grade Solid-state LiDAR Production Line Was Launched
13.3.2021 05:30:00 EET | Business Wire | Press release
RoboSense ( https://robosense.ai/) announced the launch of China’s first automotive-grade solid-state LiDAR production line and would start mass production and delivery of the automotive-grade solid-state LiDAR RS-LiDAR-M1 for contract projects in Q2 this year.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210312005303/en/
(Photo: Business Wire)
At the CES2021 in January this year, RoboSense has officially unveiled the SOP version of the automotive-grade LiDAR RS-LiDAR-M1, which features a slim design, excellent performance, and reliable point cloud quality. Since July last year, the RS-LiDAR-M1 has successively received a number of orders for mass-production vehicle models around the world, among which, the first customer was an OEM from North America. In December last year, the RS-LiDAR-M1 samples were shipped to this OEM customer in batches, and became the world's first mass-production-ready automotive-grade MEMS solid-state LiDAR delivered.
Two days ago, Inceptio released the self-driving system "Xuanyuan" equipped with RoboSense solid-state LiDAR, and the two parties announced the partnership that the mass-produced L3 heavy-duty freight truck equipped with "Xuanyuan" system will be launched on the market by the end of 2021.
As a world-leading smart LiDAR supplier, RoboSense has reached in-depth cooperation with Inceptio from 2019 to provide high-performance automotive-grade MEMS solid-state LiDAR RS-LiDAR-M1 for Inceptio’s "Xuanyuan" system, the first full-stack self-developed autonomous trucking system for mass production. Inceptio develops the ULRS (ultra-long-range sensing), ARC (adaptive robust control) and FEAD (fuel-efficient autonomous driving) algorithms, and the ULRS can make the system perceive an ultra-long distance of up to 1,000 meters with a margin of error standing below 5%.
In June 2019, Inceptio has worked with Dongfeng Trucks and SINOTRUK respectively to developed L3 autonomous heavy-duty trucks. By the end of 2021, the mass-produced L3 heavy-duty trucks equipped with Inceptio’s "Xuanyuan" system with RoboSense LiDAR inside will be delivered to clients.
About RoboSense
Founded in 2014, RoboSense (Suteng Innovation Technology Co., Ltd.) is the leading provider of Smart LiDAR Sensor Systems incorporating LiDAR sensors, AI algorithms and IC chipsets, that transform conventional 3D LiDAR sensors to full data analysis and comprehension systems. Market-oriented, the company provides customers with various Smart LiDAR perception system solutions, including the MEMS and Mechanical types LiDAR HWs, fusion HW unit, and the AI-based fusion systems. To date, RoboSense LiDAR systems have been widely applied to the future mobility, including autonomous driving passenger cars, RoboTaxi, RoboTruck, RoboBus, automated logistics vehicles and intelligent road by domestic and international autonomous driving technology companies, OEMs, and Tier1 suppliers. https://robosense.ai/
About Inceptio
Inceptio Technology was founded in April 2018, with an aim to build a nation-wide freight network using autonomous driving trucks.
We focus on the transformation of line-haul logistics by providing a more secure, efficient, and economical Transportation-As-A-Service (Taas) to logistic customers. This is to be achieved with our automotive grade L3/L4 autonomous driving software/ hardware, developed in collaboration with major automotive manufacturers, fully integrated with mass-produced heavy-duty freight trucks. With our advanced technology and seasoned operation team, we envision to develop the most trustworthy autonomous freight service network.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210312005303/en/
Contact information
Press Contact
Cassie Gong, RoboSense PR Manager
86-15507590175
sqgong@robosense.ai
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 13:38:00 EEST | Press release
For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will
Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital18.9.2026 12:48:00 EEST | Press release
Estithmar Holding Q.P.S.C. announced the completion of the transfer of a 48.68% stake in Shahba Bank to Masaref Holding LLC, subsidiary of Estithmar Capital, Estithmar Holding’s financial services and investments arm. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918807909/en/ Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital (Photo: AETOSWire) As a shareholder, Masaref Holding intends to support the assessment of proposals aimed at strengthening Shahba Bank’s financial, operational and technological capabilities, including potential capital enhancement, branch network expansion, and the development of products and services for individuals, businesses and SMEs. The proposals may include modernizing banking and operational systems, develop digital services, and strengthen governance, compliance, risk management and cybersecurity to enhance
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom